Utilizing TRIPS Flexibilities for Public Health Protection Through South-South Regional Frameworks
(2004; 110 pages) [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoTHE SOUTH CENTRE
Ver el documentoPREFACE
Ver el documentoABBREVIATIONS
Ver el documentoEXECUTIVE SUMMARY
Abrir esta carpeta y ver su contenidoI. INTRODUCTION
Abrir esta carpeta y ver su contenidoII. INTELLECTUAL PROPERTY AND ACCESS TO ESSENTIAL MEDICINES IN DEVELOPING COUNTRIES
Cerrar esta carpetaIII. CONSTRAINTS ON NATIONAL EFFORTS TO IMPLEMENT TRIPS FLEXIBILITIES FOR PUBLIC HEALTH PURPOSES
Ver el documentoIII.1 Lack of Technical Expertise to Incorporate and Implement TRIPS Flexibilities in National Law and Policy
Ver el documentoIII.2 Insufficient Domestic Research and Manufacturing Capacities in the Pharmaceutical Sector
Ver el documentoIII.3 Insufficient Technical and Infrastructural Capacities for Medicines Regulation
Ver el documentoIII.4 Difficulties in Establishing Efficient Pharmaceutical Management and Procurement Systems
Ver el documentoIII.5 Bilateral and other TRIPS-plus Pressures
Ver el documentoIII.6 Difficulties in Tackling Anti-Competitive Practices and Abuse of Intellectual Property Rights
Abrir esta carpeta y ver su contenidoIV. OVERCOMING CONSTRAINTS IN THE USE OF TRIPS FLEXIBILITIES THROUGH SOUTH-SOUTH REGIONAL FRAMEWORKS
Abrir esta carpeta y ver su contenidoV. CONCLUSIONS AND RECOMMENDATIONS
Ver el documentoBIBLIOGRAPHY
Ver el documentoBACK COVER
 

III.1 Lack of Technical Expertise to Incorporate and Implement TRIPS Flexibilities in National Law and Policy

The flexibilities afforded by TRIPS can only be utilized if they are incorporated into a country's domestic legislation. This is a first and necessary step in any attempt to use the flexibilities for public health purposes. It is therefore important that countries enact legislations that allow them full flexibility. However, many developing countries have not incorporated the TRIPS flexibilities into their laws for various reasons. What the TRIPS Agreement permits and what countries actually do are two different things. In the end, it is national law and practice that will be decisive, both in terms of providing access to medicines, and in establishing a domestic framework in which TRIPS rules will be interpreted. One major reason many developing countries have not incorporated TRIPS flexibilities into their national laws is lack of technical expertise.

Virtually all national patent systems of developing countries are modelled on European and United States patent laws. These are often based either upon colonial statutes or on laws crafted with the help of technical assistance from WIPO and the patent offices of developed countries.38 Most of the technical assistance that has gone to these countries, however, is more concerned with compliance with the provisions relating to the rights of the patent holders rather than the application of flexibilities within the multilateral framework to promote and protect public health.39

38 Love (2001).
39 Balasubramaniam (2002).


Another problem that exacerbates the lack of technical expertise to implement TRIPS flexibilities in national laws is the inability to access information on best practices. Developing countries are generally not aware of the measures undertaken by their counterparts around the world. As a result, even countries within a region with similar or the same access problems adopt different strategies, with varying degrees of success. More importantly, while most developed countries are quick to provide assistance and to give examples of best practices on how to protect patent rights, there is never a best practice guide or technical assistance, for example, on the extensive use by the United States of compulsory licensing or antitrust legislation to curb abuse of patent rights and serve other public interest purposes.40

40 For further discussion on the use of compulsory licensing in the United States see Reichman and Hasenzahl (2003).


The lack of expertise has also increased the likelihood that frivolous patents or even patents on excluded subject matter will be issued. Under the TRIPS Agreement, states may, for example, exclude from patentability diagnostic, therapeutic and surgical methods for the treatment of humans or animals as well as plants and animals other than micro-organisms and new uses of known products. These exceptions are rendered nugatory in the absence of expertise. In the Philippines, for example, patent examiners routinely rely on the issuance of United States or European patents as a precondition to the grant of a Philippine patent, notwithstanding the fact that Philippine patent law excludes certain subject matter that may be allowed under the United States and European patent laws such as business methods and computer programmes.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019